Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics of Fulacimstat in Subjects With Renal Impairment
NCT03402438Phase 1Completed
- Sponsor
- Bayer
- Start
- Feb 2018
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fulacimstat in diabetic kidney disease (DKD) and left ventricular dysfunction (4 arms), sponsored by Bayer. Primary endpoints: Area under the concentration vs. time curve from zero to infinity, Maximum observed drug concentration and 2 more. Started Feb 2018; status: completed.
02
Drugs
fulacimstat
03
Conditions
diabetic kidney disease (DKD)left ventricular dysfunction
Beyond the preview
Go deeper on NCT03402438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03402438.